A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever

BACKGROUND: Typhoid fever remains a significant cause of morbidity and mortality in developing countries especially in children ≤5 years old. Although the widely available unconjugated Vi polysaccharide vaccines are efficacious, they confer limited, short-term protection and are not approved for you...

Descripción completa

Detalles Bibliográficos
Autores principales: Cartee, Robert T., Thanawastien, Ann, Griffin IV, Thomas J., Mekalanos, John J., Bart, Stephan, Killeen, Kevin P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964911/
https://www.ncbi.nlm.nih.gov/pubmed/31905228
http://dx.doi.org/10.1371/journal.pntd.0007912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964911/
https://www.ncbi.nlm.nih.gov/pubmed/31905228
http://dx.doi.org/10.1371/journal.pntd.0007912

Ejemplares similares